Key result
Pretreatment with cannabidiol oil (26 mg/kg) significantly improved kidney function, oxidative stress, and inflammatory markers, including reducing IL-6 levels compared to doxorubicin alone.
Why the study?
The study was conducted to investigate the potential of cannabidiol for protection against renal syndrome.
Does cannabidiol mitigate doxorubicin-induced nephrotoxicity, inflammation, and oxidative stress in a rat model?
Does cannabidiol mitigate doxorubicin-induced nephrotoxicity, inflammation, and oxidative stress in a rat model?
Absolute Event Rate: 282.44% vs 393.94%
p-value: p=<0.0001
Cannabidiol oil mitigates doxorubicin-induced nephrotoxicity in rats through anti-inflammatory and antioxidant mechanisms.
Extends preclinical evidence for CBD renoprotection in doxorubicin models; leaves open translation to clinical use.
Nephropathy is the decline in kidney function. A promising treatment for numerous types of illness is using natural materials as natural chemical compounds. The inquiry was conducted to investigate cannabidiol (CBD) potential for renal syndrome protection. The five equal groups of fifty male Sprague-Dawley rats weighing 150 ± 25 g each were designed; group I received distilled water orally, while group II got an intraperitoneal injection of doxorubicin (18 mg/kg bwt). Group III received CBD (26 mg/kg bwt) orally, while group IV received 1 ml of CBD (26 mg/kg bwt) and group V received trimetazidine (10 mg/kg bwt), in addition to a single intraperitoneal dose of doxorubicin (18 mg/kg bwt) on the 11th day for both groups (IV, V). The administration of CBD (26 mg/kg bwt) led to a noticeable improvement in oxidative stress parameters (SOD and GSH) in rats by significantly lowering enzyme activity (ALT and AST), as well as serum creatinine and urea, IL-6, and MDA, confirming the anti-inflammatory accuracy of CBD linked to significant lowering to IL6R DNA frequency concentration in line with histopathology results. As a result of its anti-inflammatory and antioxidant capabilities, cannabidiol may have protective quality, and CBD medication could be related to controlling renal problems.
No takes yet. Share an insight, caveat, or question.
Soliman et al. (2023) studied Doxorubicin-induced nephrotoxicity (n=50). Cannabidiol (CBD) oil vs. Doxorubicin alone was evaluated on IL-6 levels (ng/L) (p=<0.0001). Pretreatment with cannabidiol oil (26 mg/kg) significantly improved kidney function, oxidative stress, and inflammatory markers, including reducing IL-6 levels compared to doxorubicin alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: